20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer (NSCLC)...
21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes Mouse studies suggest inhibiting FST could help treat insulin resistance and glucose intolerance. In a genetic mouse model of glucose intolerance and hyper insulinemia, liver-specific knockdown of FST decreased hepatic glucose production, serum insulin...
03:28 , Jan 19, 2018 |  BC Innovations  |  Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters that...
00:09 , Dec 2, 2017 |  BC Extra  |  Preclinical News

Low levels of myostatin may impair muscular atrophy and dystrophy treatments

In a paper published in Nature Communications, researchers from University College London and colleagues showed that the myostatin (MSTN; GDF8) pathway is downregulated in muscle wasting or atrophying diseases, providing a potential explanation for why...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

PB01: Phase I started

Paranta began a double-blind, placebo-controlled, international Phase I trial to evaluate single and multiple ascending doses of inhaled PB01 in healthy volunteers. Paranta Biosciences Ltd., Richmond, Australia   Product: PB01   Business: Pulmonary   Molecular target: NA...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

AAV1-FS344: Phase I/IIa data

A dose-escalation Phase I/IIa trial in 6 patients with Becker muscular dystrophy showed that AAV1-FS344 given by direct bilateral intramuscular quadriceps injections improved 6MWT in 4 patients. In cohort 1 (n=3), 3*1011 vg/kg/leg AAV1-FS344 improved...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Follistatin-like 1 (FSTL1) Mouse and cell culture studies suggest inhibiting FSTL1...
08:00 , Feb 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds MicroRNA-198 (miR-198); follistatin-like 1 (FSTL1) Patient sample and cell culture studies suggest inhibiting miR-198 could help...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

AAV1-FS344 regulatory update

Milo said FDA granted Orphan Drug designation to AAV1-FS344 to treat Becker and Duchenne muscular dystrophy. The adeno-associated virus (AAV) vector encoding follistatin is in a Phase I/II trial for Becker muscular dystrophy and inclusion...
07:00 , Sep 24, 2012 |  BioCentury  |  Emerging Company Profile

Arcarios: Protecting chondrocytes

Current treatments for osteoarthritis treat the symptoms and relieve pain, but do not target the cause of the disease. Arcarios B.V. has established a preclinical pipeline of compounds to slow or prevent progression of bone...